AU5331499A - Indole spla2 inhibitors - Google Patents
Indole spla2 inhibitorsInfo
- Publication number
- AU5331499A AU5331499A AU53314/99A AU5331499A AU5331499A AU 5331499 A AU5331499 A AU 5331499A AU 53314/99 A AU53314/99 A AU 53314/99A AU 5331499 A AU5331499 A AU 5331499A AU 5331499 A AU5331499 A AU 5331499A
- Authority
- AU
- Australia
- Prior art keywords
- spla2 inhibitors
- indole spla2
- indole
- inhibitors
- spla2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 title 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9510998P | 1998-08-03 | 1998-08-03 | |
| US60095109 | 1998-08-03 | ||
| PCT/US1999/017460 WO2000007591A1 (en) | 1998-08-03 | 1999-08-02 | INDOLE sPLA2 INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU5331499A true AU5331499A (en) | 2000-02-28 |
Family
ID=22249729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU53314/99A Abandoned AU5331499A (en) | 1998-08-03 | 1999-08-02 | Indole spla2 inhibitors |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6608099B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1100493A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002522386A (cg-RX-API-DMAC7.html) |
| AU (1) | AU5331499A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2338727A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2000007591A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002522386A (ja) * | 1998-08-03 | 2002-07-23 | イーライ・リリー・アンド・カンパニー | インドールsPLA2インヒビター |
| AU2001236440A1 (en) * | 2000-01-25 | 2001-08-07 | Eli Lilly And Company | Method for the treatment of inflammation with spla2 inhibitors |
| AU2001232734A1 (en) * | 2000-03-09 | 2001-09-17 | Eli Lilly And Company | Compositions containing potential spla2 inhibitors for the treatment of pain |
| CN1450893A (zh) * | 2000-07-14 | 2003-10-22 | 伊莱利利公司 | 治疗脓毒症的方法 |
| JP2005527466A (ja) | 2001-08-09 | 2005-09-15 | イーライ・リリー・アンド・カンパニー | sPLA2インヒビターとしてのシクロヘプトBインドール誘導体 |
| JP2005527464A (ja) * | 2001-08-09 | 2005-09-15 | イーライ・リリー・アンド・カンパニー | sPLA2インヒビターとしてのシクロヘプタBインドール誘導体 |
| AUPS282602A0 (en) | 2002-06-07 | 2002-06-27 | Garvan Institute Of Medical Research | Method of inhibiting cell proliferation |
| EP1479677A1 (en) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | New indole derivatives as factor xa inhibitors |
| CA2565387A1 (en) * | 2004-05-03 | 2005-11-17 | Ilypsa, Inc. | Modulation of lysophosphatidylcholine and treatment of diet-induced conditions |
| MX2008005661A (es) * | 2005-11-03 | 2008-12-15 | Ilypsa Inc | Inhibidores de fosfolipasa, que incluyen inhibidores de fosfolipasa multivalente, y uso de los mismos, que incluyen como inhibidores de fosfolipasa localizadas en el lumen. |
| JP2009514883A (ja) * | 2005-11-03 | 2009-04-09 | イリプサ, インコーポレイテッド | アザインドール化合物およびホスホリパーゼa2インヒビターとしてのその使用 |
| EP1948602A2 (en) * | 2005-11-03 | 2008-07-30 | Ilypsa, Inc. | Indole compounds having c4-amide substituents and use thereof as phospholipase-a2 inhibitors |
| EP1960356A2 (en) * | 2005-11-03 | 2008-08-27 | Ilypsa, Inc. | Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors |
| EP1948604A1 (en) * | 2005-11-03 | 2008-07-30 | Ilypsa, Inc. | Indole compounds having c4-acidic substituents and use thereof as phospholipase-a2 inhibitors |
| CN107233337A (zh) | 2009-04-29 | 2017-10-10 | 阿马里纳药物爱尔兰有限公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL109311A0 (en) | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
| IL109309A (en) | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
| EP1950200B1 (en) * | 1994-04-01 | 2012-01-11 | Eli Lilly And Company | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor |
| US5641800A (en) * | 1994-07-21 | 1997-06-24 | Eli Lilly And Company | 1H-indole-1-functional sPLA2 inhibitors |
| JP2002522386A (ja) * | 1998-08-03 | 2002-07-23 | イーライ・リリー・アンド・カンパニー | インドールsPLA2インヒビター |
| CA2338855A1 (en) * | 1998-08-03 | 2000-02-17 | Eli Lilly And Company | Indole spla2 inhibitors |
-
1999
- 1999-08-02 JP JP2000563276A patent/JP2002522386A/ja not_active Withdrawn
- 1999-08-02 AU AU53314/99A patent/AU5331499A/en not_active Abandoned
- 1999-08-02 WO PCT/US1999/017460 patent/WO2000007591A1/en not_active Ceased
- 1999-08-02 CA CA002338727A patent/CA2338727A1/en not_active Abandoned
- 1999-08-02 US US09/762,070 patent/US6608099B1/en not_active Expired - Fee Related
- 1999-08-02 EP EP99938937A patent/EP1100493A4/en not_active Withdrawn
-
2003
- 2003-03-21 US US10/395,657 patent/US7026348B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1100493A4 (en) | 2001-10-24 |
| US6608099B1 (en) | 2003-08-19 |
| WO2000007591A1 (en) | 2000-02-17 |
| CA2338727A1 (en) | 2000-02-17 |
| EP1100493A1 (en) | 2001-05-23 |
| JP2002522386A (ja) | 2002-07-23 |
| US7026348B2 (en) | 2006-04-11 |
| US20030191175A1 (en) | 2003-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU8030598A (en) | Indole compounds as cox-2 inhibitors | |
| AU3140695A (en) | 1h-indole-1-functional spla2 inhibitors | |
| AU2001274009A1 (en) | Substituted indoles as parp inhibitors | |
| IL138387A0 (en) | Enzyme inhibitors | |
| AU6229699A (en) | Beta-amyloid formation inhibitors | |
| AU5633300A (en) | Indole compounds | |
| EP1100493A4 (en) | SPLA 2 INHIBITORS? OF THE INDOLTYPS | |
| AU1576000A (en) | Loudspeaker | |
| AU3703499A (en) | Substituted indolinones as kinase inhibitors | |
| AU2723099A (en) | Tryptase inhibitors | |
| AU5589298A (en) | Phenyl acetamides as spla2 inhibitors | |
| GB9825988D0 (en) | Indole derivatives | |
| AU4685799A (en) | Telomerase inhibitors | |
| AU7126900A (en) | Enzyme inhibitors | |
| AU7450898A (en) | Indole compounds | |
| AU1393900A (en) | Morpholino-ethoxybenzofuran protease inhibitors | |
| AU2373600A (en) | Novel spla2 inhibitors | |
| AU3235100A (en) | Prothease inhibitors | |
| GB9924522D0 (en) | Enzyme inhibitors | |
| GB9816358D0 (en) | Enzyme inhibitors | |
| AU2849399A (en) | Monobactam enzyme inhibitors | |
| AU1149797A (en) | Naphthyl glyoxamides as spla2 inhibitors | |
| AU1279899A (en) | N,n-diethylglycolamido ester prodrugs of indole spla2 inhibitors | |
| PL343708A1 (en) | Spla2 | |
| AU7127000A (en) | Enzyme inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |